[go: up one dir, main page]

WO2004035783A3 - Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway - Google Patents

Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway Download PDF

Info

Publication number
WO2004035783A3
WO2004035783A3 PCT/EP2003/050655 EP0350655W WO2004035783A3 WO 2004035783 A3 WO2004035783 A3 WO 2004035783A3 EP 0350655 W EP0350655 W EP 0350655W WO 2004035783 A3 WO2004035783 A3 WO 2004035783A3
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
complexes
tnf
signalling pathway
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/050655
Other languages
French (fr)
Other versions
WO2004035783A2 (en
WO2004035783A9 (en
Inventor
Tewis Bouwmeester
Bettina Huhse
Angela Bauch
Heinz Ruffner
Andreas Bauer
Bernhard Kuester
Giulio Superti-Furga
Ulrich Kruse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellzome GmbH
Original Assignee
Cellzome GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020021809 external-priority patent/EP1403282A1/en
Application filed by Cellzome GmbH filed Critical Cellzome GmbH
Priority to AU2003298261A priority Critical patent/AU2003298261A1/en
Publication of WO2004035783A2 publication Critical patent/WO2004035783A2/en
Publication of WO2004035783A9 publication Critical patent/WO2004035783A9/en
Publication of WO2004035783A3 publication Critical patent/WO2004035783A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the protein complexes of the Tumor necrosis factor -α- (TNF-α)-signalling pathway. component proteins of the said complexes, fragments and derivatives of the component proteins, and antibodies specific to the complexes. The present invention also relates to methods for use of the complexes of the TNF-α-signalling pathway and their interaction in, inter alia, screening, diagnosis, and therapy, as well as to methods of preparing the complexes. Furthermore the invention relates to siRNA-oligonucleotides having a significant effect on the expression of the proteins of the complexes of the invention.
PCT/EP2003/050655 2002-09-26 2003-09-24 Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway Ceased WO2004035783A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003298261A AU2003298261A1 (en) 2002-09-26 2003-09-24 Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20020021809 EP1403282A1 (en) 2002-09-26 2002-09-26 Protein complexes of the Tumor necrosis factor-alpha (TNF-alpha) signalling pathway
EP02021809.5 2002-09-26
EP03100274 2003-02-10
EP03100274.4 2003-02-10

Publications (3)

Publication Number Publication Date
WO2004035783A2 WO2004035783A2 (en) 2004-04-29
WO2004035783A9 WO2004035783A9 (en) 2004-09-30
WO2004035783A3 true WO2004035783A3 (en) 2004-11-11

Family

ID=32109134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/050655 Ceased WO2004035783A2 (en) 2002-09-26 2003-09-24 Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway

Country Status (2)

Country Link
AU (1) AU2003298261A1 (en)
WO (1) WO2004035783A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697407A2 (en) * 2003-11-28 2006-09-06 Medical Research Council Regulation involving abin-2
WO2009067800A1 (en) 2007-11-27 2009-06-04 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof
ES2806498T3 (en) 2015-06-08 2021-02-17 Arquer Diagnostics Ltd Methods for the analysis of a urine sample
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
CN113447658B (en) * 2021-07-01 2022-04-19 浙江大学 Kit for detecting anti-peroxiredoxin-1-IgG antibody
CN118005729B (en) * 2024-02-27 2024-11-15 中国农业大学 Polypeptide with tyrosinase inhibitory activity and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044626A1 (en) * 1998-03-05 1999-09-10 Tularik Inc. Suppressors of death domains

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044626A1 (en) * 1998-03-05 1999-09-10 Tularik Inc. Suppressors of death domains

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DENG L ET AL: "Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 103, no. 2, 13 October 2000 (2000-10-13), pages 351 - 361, XP002232447, ISSN: 0092-8674 *
JIANG Y ET AL: "Prevention of constitutive TNF receptor 1 signaling by silencer of death domains", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 283, no. 5401, 22 January 1999 (1999-01-22), pages 543 - 546, XP002232446, ISSN: 0036-8075 *
LEE JUSTINE C ET AL: "DEDD regulates degradation of intermediate filaments during apoptosis", JOURNAL OF CELL BIOLOGY, vol. 158, no. 6, 16 September 2002 (2002-09-16), &, pages 1051 - 1066, XP002274488, ISSN: 0021-9525 *
LOCKSLEY R M ET AL: "THE TNF AND TNF RECEPTOR SUPERFAMILIES: INTEGRATING MAMMALIAN BIOLOGY", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 104, 23 February 2001 (2001-02-23), pages 487 - 501, XP002951130, ISSN: 0092-8674 *
SAKURAI HIROAKI ET AL: "Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 38, 19 September 2003 (2003-09-19), &, pages 36916 - 36923, XP002274489, ISSN: 0021-9258 *
VAN HUFFEL S ET AL: "Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 32, 10 August 2001 (2001-08-10), pages 30216 - 30223, XP002955138, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU2003298261A8 (en) 2004-05-04
AU2003298261A1 (en) 2004-05-04
WO2004035783A2 (en) 2004-04-29
WO2004035783A9 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
WO2003087831A3 (en) Proteins involved in breast cancer
AU2002305450A1 (en) Proteomimetic compounds and methods
AU2003271174A1 (en) Double specific antibodies substituting for functional protein
WO2004031400A3 (en) Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
PL1641483T3 (en) Fusion proteins
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
GEP20105022B (en) Use of polypeptides of the cupredoxin family in cancer therapy
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2007098198A3 (en) Modulation of bone formation
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2004012673A3 (en) Methods and reagents relating to inflammation and apoptosis
WO2004035783A3 (en) Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway
WO2004069860A3 (en) Isg15-conjugated proteins
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
IL207012A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2004031354A3 (en) Human sarcoma-associated antigens
WO2004078130A3 (en) Posh interacting proteins and related methods
WO2003059943A3 (en) Conformation-specific, protein kinase binding peptides and related methods and products
WO2003075014A3 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2004031242A3 (en) Protein complexes involved in neurological diseases
WO2004009619A3 (en) Protein complexes of the tip60 transcriptional activator protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP